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Abstract 23 
A gene therapeutic platform needs to be both efficient and safe. The criterion of safety is 24 
particularly important for diseases like hepatocellular carcinoma (HCC) which develop in a 25 
background of an already compromised liver. Gene vectors can be constructed either by 26 
targeting HCC or by detargeting liver and/or other major organs. miRNA based negative 27 
detargeting has gained considerable attention in recent times due to its effectiveness and the 28 
ease with which it can be adapted into current gene delivery vectors. In this study, we provide 29 
a proof-of-concept of using miRNA199a as a negative targeting agent. We introduced vectors 30 
harbouring reporters with miRNA199a binding sites in cells expressing high endogenous 31 
levels of miRNA199a and compared the reporter expression in HCC cells with low 32 
endogenous miRNA199a. We observed that the expression of reporters with miRNA199a 33 
binding sites is significantly inhibited in miRNA199a positive cells whereas minimal effect 34 
was observed in miRNA199a negative HCC cells. In addition, we created a post-35 
transcriptionally regulated suicide gene therapeutic system based on cytosine deaminase 36 
(CD)/ 5-fluoro cytosine (5-FC) exploiting miRNA199a binding sites and observed 37 
significantly lower cell death for miRNA199a positive cells. Furthermore, we observed a 38 
decrease in levels of miRNA199 in 3D tumourspheres of miRNA199a positive Hepa1-6 cells 39 
and a reduction in the inhibition of reporter expression after transfection in these 3D models 40 
when compared with 2D Hepa1-6 cells. In summary, we provide evidences of miRNA199a 41 
based post-transcriptional detargeting with relevance to HCC gene therapy. 42 
 43 
 44 
 45 
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Introduction 47 
Hepatocellular carcinoma (HCC) accounts for the majority of liver cancer, one of the cancer 48 
types with high incidence-to-mortality rates 1. The limitation of available therapies, especially 49 
at advanced stages, is clearly highlighted by their palliative nature and rising trends in 50 
disease-associated mortality and morbidity rates 1, 2. Moreover, the presence of underlying 51 
liver dysfunction in most patients limit the application of conventional therapies like radio 52 
and chemotherapy 3. Sorafenib, with only a modest survival benefit, is the only FDA 53 
approved drug for late stage HCC 4. Given the aetiology of HCC, targeted therapies which 54 
can limit the treatment to HCC while sparing the liver could have a significant therapeutic 55 
benefit 5. In this regard, gene therapy, which provides several strategies that can be exploited 56 
to target a certain cell type, may be particularly attractive 5, 6. 57 
Gene therapy offers different approaches for cancer targeted gene delivery, these include (but 58 
are not limited to) modification of gene delivery vehicle (vector) and modification of the 59 
therapeutic payload (controlled expression of the transgene) 7. The former mostly comprises 60 
of the use of capsid modified viral vectors with an altered tropism, displaying preference for 61 
cancer cells 6. Limiting the expression of the therapeutic gene in cancer cells by 62 
transcriptional targeting i.e. exploiting tumor specific promoters is another strategy with 63 
proven efficacy 8, 9, however, this method is limited by the number of available promoters 64 
with a strong HCC specificity 6, 10. Post-transcriptional regulation of gene expression by 65 
utilizing cell-specific endogenous microRNAs (miRNAs) is an emerging approach for 66 
targeted gene expression. Since the first evidence of effective application of this approach in 67 
antigen presenting cells 11, a number of studies have successfully used binding sites of tissue, 68 
or disease specific miRNAs for regulating transgene expression 12-14. In this negative 69 
targeting method, binding sites of miRNA expressed at high levels in target cells is 70 
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incorporated at the UTRs of transgene and as a result transgene expression gets inhibited in 71 
those cells (Figure 2a) 15.  72 
In this proof-of-concept study, we demonstrate miRNA199a based detargeting after gene 73 
delivery. First, we probed the expression of miRNA199a in cryopreserved human 74 
hepatocytes, HepaRG and a panel of HCC and non-HCC cell lines. After observing a 75 
significant downregulation of miRNA199a in HCC and non-HCC tumor cell lines (except for 76 
Hepa1-6 which expressed miRNA199a at levels comparable to primary hepatocytes and 77 
HepaRG cells), we constructed expression vectors with miRNA199a binding sites at the 3’-78 
UTR of reporters eGFP and gaussia luciferase (GLuc) and transfected both miRNA199a 79 
positive and negative cells with these plasmids. A significant inhibition of the expression of 80 
reporter was observed in cells with high endogenous miRNA199a levels while negligible 81 
effects were seen in others. These findings were further validated by targeted gene directed 82 
enzyme prodrug therapy (GDEPT) using cytosine deaminase/5-fluorocytosine (CD/5-FC) 83 
system. Next, we demonstrate that the inhibition of miRNA199 in miRNA199 positive cells 84 
can rescue the expression of transgenes with miR199a binding sites while its overexpression 85 
with miRNA mimic can inhibit the same in miRNA199a negative HCC cells. 86 
Furthermore, the possibility of delivering these constructs with Adeno associated virus 87 
(AAV) based delivery system was explored and the results obtained with transfection 88 
experiments were corroborated. Additionally, we discovered that the levels of miRNA199a is 89 
downregulated in CD133+ CD44+ Oct4+ expressing tumorspheres of Hepa1-6 illustrating the 90 
potential to use miRNA199a to target these 3D models of HCC. Finally, we demonstrate that 91 
tumorspheres of Hepa1-6 can be efficiently targeted with miRNA199a binding site 92 
containing expression vectors. In conclusion, this study provides evidence that negative 93 
targeting after gene delivery can be achieved in hepatocytes by exploiting miRNA199a and 94 
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suggests that this principle of negative targeting with miRNA199a could be exploited for 95 
other cell types expressing high endogenous miRNA199a levels. 96 
Results 97 
miRNA199a is downregulated in HCC and other cancer cell lines 98 
To investigate the expression pattern of miRNA199a, we performed real time qPCR on 99 
cDNA obtained from total RNA extracted from primary hepatocytes, HepaRG and a panel of 100 
HCC and non-HCC cell lines. After quantifying the amounts of miRNA199a with qPCR, 101 
high levels of miRNA199a was observed in cryopreserved human primary hepatocytes and 102 
HepaRG cells (92 copies per 1000 copies of control) (Figure 1a). Similarly, the HCC cell 103 
line Hepa1-6 was found to have higher copies of miRNA199a (498 copies per 1000 copies of 104 
RNU control) (Figure 1a). In HCC cell lines Hep3B, PLC/PRF/5, SKHep1, and SNU423, no 105 
copies of miRNA199a was detected using this method. Similarly, little or no expression of 106 
miRNA199a was observed in the non-HCC cancer cell lines used in this study (Figure 1b). 107 
Together, these results indicated that miRNA199a is downregulated in HCC as well as non-108 
HCC tumor cell lines and established Hepa1-6 as a model to study different aspects of 109 
miRNA199a.  110 
Incorporation of miRNA199a binding sites at the 3’-UTR of a transgene allows negative 111 
targeting of cells with high endogenous expression of miRNA199a 112 
To explore the effects of inclusion of miRNA199a binding sites at the 3’-UTR of a transgene, 113 
we constructed expression plasmids with GLuc with 3 miRNA199a binding sites at the 3’-114 
UTR (CMV-GLuc-miR199a*3). These plasmids were then transfected into miRNA199a 115 
positive cell lines HepaRG, and Hepa1-6 as well as miRNA199a negative HCC, and non-116 
HCC cell lines. The percentage of secreted luciferase after transfection with CMV-GLuc-117 
miR199a*3 was observed to be significantly lower when compared to that after transfection 118 
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with CMV-GLuc for both HepaRG (p<0.005), and Hepa1-6 (p<0.001) (Figure 2b). 119 
Interestingly, the decrease in luciferase expression after transfection with CMV-GLuc-120 
miR199a*3 in HepaRG cells was observed to be 2.94 times (p<0.001) higher than that 121 
observed for Hepa1-6 which correlated with the copies of miRNA199a present in those cells. 122 
As expected no significant decrease in GLuc expression was observed in HCC cell lines 123 
Hep3B, SKHep1, PLC/PRF/5, and SNU423 (Figure 2c) as well as non-HCC tumor cell lines 124 
(Figure 2d) after transfection with CMV-GLuc-miR199a*3. To further confirm this observed 125 
miRNA199a mediated post transcriptional control of gene expression, we used a second 126 
reporter eGFP. Hepa1-6 cells were transfected with either CMV-eGFP or CMV-eGFP-127 
miR199a*3 and GFP positive cells were quantified by flow cytometry. Like the GLuc 128 
reporter, a significantly reduced GFP expression was observed after transfection with CMV-129 
eGFP-miR199a*3 when compared to CMV-eGFP (p<0.001) (Figure 2e). Together, these 130 
results provided evidence that the incorporation of miRNA199a binding sites at the 3’-UTR 131 
of a gene can inhibit its expression in cells with high endogenous levels of miRNA199a. 132 
Overexpression of miRNA199a in HCC cells inhibits expression of transgene with its 133 
binding sites at the 3’-UTR while its inhibition rescues the expression of the same in 134 
cells with high endogenous expression levels 135 
Next, we altered miRNA199a levels in Hepa1-6 and HCC cells using inhibitors and mimics 136 
to define miRNA199a’s role in the expression of reporters with binding sites incorporated in 137 
the 3’-UTR. We co-transfected miRNA199a inhibitor with either CMV-eGFP-199a*3 or 138 
CMV-GLuc-miR199a*3 and compared expression to CMV-GLuc, or CMV-eGFP controls. 139 
A significant increase (p<0.05) in the percentage of GFP positive cells was observed after co-140 
transfection of Hepa1-6 with CMV-eGFP-miR199a*3 and miRNA199a inhibitor when 141 
compared to transfection with CMV-eGFP-miR199a*3 (both reported as relative to CMV-142 
eGFP) (Figure 3a, b). Similarly, miRNA199a inhibition by co-transfection of Hepa1-6 with 143 
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CMV-GLuc-miR199a*3 and miRNA199a inhibitor resulted in a 2.9-fold increase (p<0.05) of 144 
GLuc expression when compared to GLuc expression after transfection with CMV-GLuc-145 
miR199a*3 alone (both normalized to CMV-GLuc control) (Figure 3c). In contrast, co-146 
transfection of CMV-GLuc-miR199a*3 and miRNA199a mimic in miRNA199a negative 147 
HCC cell lines Hep3B, PLC/PRF/5, SKHep1, and SNU423 resulted in a significant decrease 148 
(Figure 3d) (p<0.05) in GLuc expression when compared to CMV-GLuc-miR199a alone (all 149 
normalized to CMV-GLuc control). Taken together, these results further strengthen the 150 
observation of miRNA199a mediated post-transcriptional regulation of expression of reporter 151 
gene containing its binding sites at the 3’-UTR and provide evidence that its inhibition can 152 
rescue the expression of these reporters.  153 
Post-transcriptionally controlled gene directed enzyme prodrug therapy (GDEPT) for 154 
HCC  155 
Next, we constructed a post-transcriptionally regulated GDEPT platform based on suicide 156 
gene CD and prodrug 5-FC for gene therapy. Either CMV-CD or CMV-CD-miR199a*3 were 157 
transfected into miRNA199a positive Hepa1-6 as well as miRNA199a negative HCC cell 158 
lines Hep3B, PLC/PRF/5, SKHep1, and SNU423. We studied both cell proliferation and cell 159 
death (Figure 4) after transfection with CMV-CD, and CMV-CD-miR199a*3. A 1.8-fold 160 
higher proliferation rate was observed for Hepa1-6 after transfection with CMV-CD-161 
miR199a*3 when compared to transfection with CMV-CD (p<0.05) and incubation with 162 
prodrug 5-FC whereas no significant difference was observed in HCC cell lines Hep3B, 163 
PLC/PRF/7, SKHep1, and SNU423 (Figure 4a). Similarly, total cell death (quantified by 164 
PI/annexin staining) was significantly lower (p<0.001) in Hepa1-6 after transfection with 165 
CMV-CD-miR199a*3 and incubation with 5-FC when compared to CMV-CD positive 166 
control (Figure 4b, c) while no significant effects were observed in HCC cell lines Hep3B, 167 
PLC/PRF/7, and SKHep1 (Figure 4b, d). These results demonstrate that a liver detargeted 168 
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GDEPT system which simultaneously targets HCC can be constructed using miRNA199a 169 
mediated post-transcriptional gene regulation. 170 
Adeno associated virus (AAV) mediated delivery of transgenes with miR199a binding 171 
site for detargeting cells containing high endogenous miRNA199a levels 172 
To examine the possibility of delivering miRNA199a based post-transcriptionally regulated 173 
reporter and therapeutic genes using AAV vectors, we constructed self-complementary AAV 174 
serotype 8 with or without miR199a binding sites at the 3’-UTR of the transgenes (scAAV8-175 
GLuc, scAAV8-GLuc-miR199a*3, scAAV8-CD, scAAV8-CD-miR199a*3). Transduction of 176 
miRNA199a positive Hepa1-6 cell line with scAAV8-GLuc-miR199a*3 resulted in a 177 
significantly reduced GLuc expression (p<0.05) when compared to scAAV8-GLuc while no 178 
significance difference in GLuc expression was observed in miRNA199a negative HCC cell 179 
lines Hep3B, PLC/PRF/5, SKHep1, and SNU423 (Figure 5b). Similarly, after transduction 180 
with scAAV8-CD-miR199a*3 and subsequent incubation with prodrug 5-FC, a 3.4-fold 181 
higher proliferation rate was observed in Hepa1-6 cells (p<0.05) when compared to scAAV8-182 
CD whereas no significant difference in cell proliferation was observed for both groups in 183 
HCC cell lines Hep3B, PLC/PRF/5, SKHep1, and SNU423 (Figure 5c). These results 184 
demonstrate the compatibility of our miRNA199a based post-transcriptionally targeted gene 185 
delivery and therapy system with AAV vector based delivery system, the most widely used 186 
delivery vector for therapeutic purposes. 187 
 CD133+ CD44+ Oct4+ enriched 3D tumorspheres can be targeted with vectors 188 
harbouring transgenes with miRNA199a binding sites at the 3’-UTR 189 
In order to assess the efficacy of miRNA199a targeting in a more complex tumor-like 190 
environment, we utilized Hepa1-6 cells grown under 3D tumorsphere culture conditions 191 
(Figure 6a).  These heterogeneous 3D tumor-like cultures have also been shown to enrich for 192 
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cancer stem cells 16. Given the reported tumor supressing roles of miRNA199a and its 193 
downregulation in cancer stem cells for other cancer types, we first investigated whether 194 
maintaining Hepa1-6 cells as 3D tumorspheres could enrich for classic cancer stem cell 195 
markers.  We quantified the levels of expression of HCC stemness markers CD44 (Figure 196 
6b), CD133 (Figure 6c), and Oct4 (Figure 6d) in these tumorspheres and observed a 197 
significant upregulation of these genes when compared to 2D grown Hepa1-6 cells (p<0.05). 198 
The increase in stemness markers correlated to a downregulation in levels of miRNA199a 199 
(Figure 6e).  200 
Next, we examined whether Hepa1-6 cells tumor-like spheroids could be efficiently targeted 201 
by the miR199a TS vectors.  To do this, we transfected these stem-cell enriched 3D 202 
tumorspheres of Hepa1-6 and 2D Hepa1-6 with CMV-GLuc-miR199a*3 and examined 203 
reported expression.  We observed a significant increase in the reporter expression in 3D 204 
tumorspheres compared to the miRNA199a expressing 2D cultures (p<0.05) (Figure 6f). 205 
Similarly, a 2.19-fold increase in GLuc expression (p<0.005) was observed after transduction 206 
of 3D tumorspheres of Hepa1-6 with scAAV8-GLuc-miR199a*3 when compared to 2D 207 
culture (Figure 6g). Using GDEPT with CD/5-FC system also resulted in a significantly 208 
higher cell death (p<0.001) in 3D tumorspheres of Hepa1-6 cells when compared to the 2D 209 
culture (Figure 6h). These results suggest that miRNA199a targeting strategies have utility in 210 
targeting more complex tumor-like spheroids and may also have utility in targeting 211 
hepatocellular CSC with decreased miRNA199 expression. 212 
Discussions 213 
miRNAs are small, untranslated, endogenous RNA molecules that efficiently regulate the 214 
expression of a gene by binding to a specific sequence in its mRNA (binding sites). In 215 
addition to having a cell specific expression pattern and being involved in several important 216 
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biological processes ranging from development to apoptosis, several miRNAs have been 217 
reported to be dysregulated in several diseases including cancer. Inclusion of binding sites of 218 
miRNAs that are downregulated in cancer while being expressed at high levels in normal 219 
cells is an attractive approach for limiting transgene expression in cancer cells. 220 
In this study we first, investigated the expression levels of miRNA199a in hepatocytes and a 221 
panel of HCC and non-HCC cell lines.  We showed that miRNA199a was significantly down 222 
regulated in HCC and non-HCC lines, while remaining high in primary hepatocytes, HepRG 223 
cells and Hepa1-6. The observation that murine Hepa1-6 cell line contains miRNA199a at 224 
levels comparable to hepatocytes allowed us to use it as a model for normal hepatocyte 225 
expression. These results were in line with other studies showing miRNA199a down 226 
regulation in HCC but expression at high levels in the cells of the liver including hepatocytes 227 
17, 18
, hepatic stellate cells19 and liver sinusoid endothelial cells 20. It has been reported as one 228 
of the key miRNAs dysregulated in HCC development and progression with a role as a 229 
diagnostic marker 21, 22 as well as a therapeutic target 23, 24. miRNA199a has also been shown 230 
to be downregulated in a number of non-liver cancers such as breast cancer 25 renal cell 231 
cancer 26 osteosarcoma 27,thyroid cancer 28 and bladder cancer 29.  232 
 In line with previous studies performed with liver-specific miRNA122a 30, 31, transfection of 233 
reporters with three miRNA199a binding sites at the 3’-UTR resulted in a significant 234 
inhibition of the reporter expression in miRNA199a positive primary hepatocytes HepaRG, 235 
and Hepa1-6 cells while no significant effects were observed in miRNA199a negative HCC 236 
and non-HCC cell lines. No effect in expression was seen when a control miRNA binding site 237 
was incorporated at the 3’-UTR (supplementary Figure 1).  Next, we generated plasmids 238 
harbouring cytosine deaminase (CD) and miRNA199a binding sites and observed 239 
significantly reduced cell death in miRNA199a positive cell Hepa1-6 after transfection and 240 
incubation with the prodrug 5-FC while in miRNA199a negative HCC cells, cell death 241 
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equivalent to CMV driven CD expression was observed. These results validated a post-242 
transcriptionally targeted suicide gene therapeutic system for HCC. Given the complete 243 
homology between murine and human miRNA199a 32, we were able to model the effects of 244 
incorporating binding sites of miRNA199a at the 3’-UTR using Hepa1-6 which was useful 245 
especially for targeted GDEPT studies which is often problematic in primary hepatocytes due 246 
to culture conditions. We chose to use perfectly complementary binding sites as imperfectly 247 
complementary binding sites can cause saturation of endogenous miRNA even at low 248 
concentration of transcripts 15, 33, similarly, utilizing perfectly complementary binding 249 
induces target RNA degradation facilitating quick turnover 34, 35. 250 
Next, we explored the possibility of constructing a targeted AAV vector harbouring our 251 
miRNA199a based post-transcriptionally regulated gene therapeutic system. Similar to 252 
reports by Peruta et al., who utilized the liver specific nature of AAV8 to construct 253 
miRNA122a based post-transcriptionally liver detargeted gene delivery system, we observed 254 
that transduction of Hepa1-6 with scAAV8-GLuc-miR199a*3 leads to a significant reduction 255 
of reporter expression when compared to scAAV8-GLuc 36. This observation was further 256 
corroborated by post-transcriptionally detargeted suicide gene therapy with scAAV8-CD-257 
miR199a*3 in Hepa1-6. Given the ability of AAV8 to transduce liver and tissues of liver 258 
origin, our system could provide an option to target disseminated tumours.  259 
In an interesting observation, we observed reduced levels of miRNA199a in 3D Hepa1-6 260 
tumorspheres of enriched in stemness markers including CD44. This observation is in line 261 
with the reported tumor suppressive role of miRNA199a in HCC and the fact that 262 
miRNA199a directly regulates the expression of stemness marker CD44 in other cancers 37, 263 
38
. While we have not directly shown the existence of cancer stem cells (CSC) in this study, 264 
others have  shown that tumorspheres derived from HCC are enriched in stem like cells and 265 
exhibit high chemoresistance 39. The potential utility of miRNA199 to target a sub-population 266 
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of CSCs is intriguing and could be explored in future studies. Although this particular study 267 
doesn’t answer the question of how and what roles miRNA199a might play in HCC stem cell 268 
biology, the decreased levels of miRNA199a in Hepa1-6 tumorspheres allowed us to not only 269 
assess the effectiveness of miRNA199a targeting in a miRNA199a negative cell population 270 
but also showed its effectiveness in terms of increased expression and increased death when 271 
used in conjunction with GDEPT in a complex 3D tumor-like environment. Similar 3D 272 
tumoursphere culture systems are widely used to recapitulate some of the tumor 273 
heterogeneity seen in vivo, and to screen for novel drug candidates while reducing the need of 274 
animal models 40, 41 .  275 
In conclusion, this proof-of-concept study establishes negative targeting based on post-276 
transcriptional gene regulation by miRNA199a in the context of HCC gene therapy. This 277 
system was found to efficiently target HCC cells with downregulation of miRNA199a while 278 
at the same time detargeting miRNA199a positive HepaRG and Hepa1-6. Furthermore, AAV 279 
based delivery of this system was found to be feasible and effective. Finally, given that 280 
miRNA199a has been reported to be downregulated in multiple cancer types, this system 281 
could be exploited to detarget any cell type with high endogenous levels of miRNA199a.  282 
Materials and Methods 283 
Cell culture 284 
Hepa1-6 cell line which expresses high levels of miRNA199a and HCC cell lines Hep3B, 285 
PLC/PRF/5, SKHep1, and SNU423 with miR199a downregulation were obtained from 286 
ATCC and maintained in DMEM media (Thermo Fisher Scientific, Scoresby, Australia) 287 
supplemented with 10% fetal bovine serum (FBS) (Gibco, Australia) and 1% 288 
penicillin/streptomycin (P/S) (Gibco, Australia). Australian Genome Research Facility 289 
(AGRF) cell line ID service was used to confirm the identity of the human cell lines. Breast 290 
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cancer cell lines T47D and MCF-7 were maintained in standard DMEM media. Melanoma 291 
cell lines 92.1, and Mel270 (gifted by Nicholas Hayward) and ovarian cancer lines SW626, 292 
CAOV3, TOV21G were grown in RPMI media (Thermo Fisher Scientific) supplemented 293 
with 10% FBS and 1% P/S. Prostate cancer cell lines LnCap and DU145 were maintained in 294 
standard DMEM media. All the other cell lines were maintained as per the ATCC 295 
recommendations. Cryopreserved primary human hepatocytes (HUM4150) and NoSpin 296 
HepaRG (NSHPRG) cells were obtained from Lonza, Australia and maintained as per the 297 
manufacturer’s protocol. 298 
Quantitative RT-PCR and quantification of miRNA levels 299 
To quantify the endogenous expression levels of miRNA199a, total RNA was isolated with 300 
trizol and cDNA was synthesized with the MystiCq microRNA cDNA Synthesis Mix (Sigma 301 
Aldrich, St. Louis, MO, United States) as per the manufacturer’s protocol. The synthesized 302 
cDNA was then used for quantitative real time PCR (qRT-PCR) with Bioline Lo-Rox Sybr 303 
(Bioline, Alexandria, Australia) in the ViiA7 RT-PCR machine (Thermo Fisher Scientific) at 304 
the following conditions: 95°C- 10mins followed by 40 cycles of 95°C- 5s, 60°C -10s and 305 
70°C -10s. The MystiCq Universal PCR (MIRUP, Sigma) and 5’- 306 
CCCAGTGTTCAGACTACCTG- 3’ primers were used to amplify miRNA199a and the 307 
amount of miR199a was calculated as number of copies per 1000 copies of RNU6 308 
(MIRCP00001) control using the formula (2^(Ct control-Ct sample))*1000. A 100% 309 
homologous nature of murine and human miRNA199a allowed usage of the same primer for 310 
amplification. Similarly, markers for the level of stemness (CD44, CD133, and Oct4) were 311 
measured relative to GAPDH control (primers listed in supplementary table 1). 312 
Construction of expression plasmids 313 
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The gene encoding GLuc with three miRNA199a-5p binding sites 314 
(GGGTCACAAGTCTGATGGACAAG*3) at the 3’-UTR was artificially synthesized 315 
(Thermo Fisher Scientific). The gene with and without miRNA binding sites was then cloned 316 
in the pscAAV-GFP (a gift from John T Gray, Addgene plasmid # 32396) using enzymes 317 
EcoRI, StuI and EcoRI, EcoRV to obtain CMV-GLuc and CMV-GLuc-miR199a*3 318 
respectively. For the construction of cytosine deaminase (CD) expressing plasmids, the gene 319 
was artificially synthesized separately and cloned in the above-mentioned plasmids replacing 320 
GLuc to obtain CMV-CD and CMV-CD-miR199a*3. A control miRNA binding site 321 
GGGTCACAAGTCTGATGGACAAG *3 was also incorporated at the 3’-UTR of reporters 322 
(Supplementary figure 1). A representation of plasmid construction has been included in 323 
Figure 5 (a).  324 
Transfection and gaussia luciferase reporter assays 325 
All transfection studies for investigating the reporter expression were performed with 326 
Lipofectamine 3000 (Thermo Fisher Scientific) in a 24 well plate as per the manufacturer’s 327 
protocol. Briefly, 30,000 cells were seeded in a 24 well plate and transfection was performed 328 
with 500ng of plasmids. 72 hours post-transfection, the amount of GLuc secreted in the 329 
media was quantified with the Pierce gaussia luciferase glow assay kit (Thermo Fisher 330 
Scientific) as per the manufacturer’s recommendations. The chemiluminescence 331 
measurement was done with the Infinite 200 Pro NanoQuant (Tecan Trading AG, 332 
Switzerland). In order to regulate the difference in transfection efficiencies across cell lines, 333 
chemiluminescence detected with CMV-GLuc-miR199a*3 was normalized with CMV-GLuc 334 
for individual cell type.  335 
Inhibition and overexpression of miR199a 336 
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For knockdown experiments in Hepa1-6 cells, 5 pmol of miRNA199a inhibitor (4464084, 337 
Life Technologies, Mulgrave, Australia) was co-transfected using Lipofectamine 3000 with 338 
either CMV-GLuc or CMV-GLuc-199a*3 and either CMV-eGFP or CMV-eGFP-miR199a*3 339 
in a 24 well plate as per the manufacturer’s protocol. Similarly, for overexpression, 340 
miRNA199a mimic (4464066, Life Technologies) was co-transfected with either CMV-GLuc 341 
or CMV-GLuc-miR199a*3. 72 hours post transfection, percentage of GFP positive cells or 342 
secreted GLuc was quantified for each group and expressed as percentage of either CMV-343 
eGFP or CMV-GLuc respectively. 344 
Cell proliferation assay 345 
Cell proliferation assay was performed with the CellTiter96 Aqueous One Solution Cell 346 
Proliferation Assay kit (Promega Corporation, Madison, WI USA). Briefly, 10,000 cells were 347 
seeded in a 96 well plate and transfected with either CMV-CD or CMV-CD-199a*3. 24 hours 348 
post-transfection, fresh media containing 10µm 5-FC was added. After 48 hours, the cells 349 
were incubated with MTS reagent as per manufacturer’s protocol and absorbance was 350 
measured at 540nm with the Infinite 200 Pro NanoQuant. Percentage proliferation was 351 
calculated for CMV-CD and CMV-CD-199a*3 for each cell line and percentage proliferation 352 
with CMV-CD-199a*3 was subtracted from that with CMV-CD to account for the difference 353 
in transfection efficiencies. 354 
Cell death assay with Annexin V/PI 355 
In order to quantify the amount of cell death after the expression of the suicide gene CD with 356 
or without miRNA199a binding site at the 3’-UTR, flow cytometry based on Annexin V/PI 357 
staining (Life Technologies) was performed as suggested by the supplier. Briefly, 30,000 358 
cells were transfected with CMV-CD or CMV-CD-199a*3 in a 24-well plate. 48 hours post 359 
transfection, the media was replaced with fresh media containing 10 µM 5-FC. After 24 360 
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hours, the cells were washed, collected and stained with Annexin V/PI.  Annexin V/PI 361 
positive cells were quantified using the FACS Canto II and data analysis was performed with 362 
FCS express 3 (BD Biosciences; North Ryde, Australia). The percentage of apoptotic cells 363 
after transfection with CMV-CD-199a*3 was normalized with CMV-CD for each cell type.   364 
Adeno-associated virus production and transduction 365 
AAV serotype 8 was produced using the triple transfection method using polyethylenimine 366 
(PEI). Briefly, HEK293 cells were seeded in 15 cm plates and transfected with pHelper 367 
(Agilent Technologies, Mulgrave, Australia), AAV8 capsid and either psc-CMV-GLuc, psc-368 
CMV-GLuc-miR199*3, psc-CMV-CD, psc-CMV-CD-miR199*3 in a 2:1:1 ratio. After 48-369 
72 hours, the cells were washed with PBS and subjected to 3 freeze-thaw cycles with 370 
ethanol/dry ice followed by incubation at 37°C to release the AAV. The crude lysate was 371 
then treated with benzonase (Sigma Aldrich), passed through the Amicon Ultrafilter 100 kDa 372 
(Sigma Aldrich) and buffer exchange was performed three times with PBS following which 373 
the end product was filtered through 0.22-micron filters. The number of vector genomes (vgs) 374 
was quantified with quantitative PCR (primers have been listed in supplementary table 1). 375 
All transduction experiments to study GLuc expression were performed in 96 well plates at 376 
an MOI of 100,000 vgs/cells and luminescence was measured as previously described. 377 
Similarly, suicide gene therapy was performed with an MTS assay after transduction of 378 
10,000 cells with 100,000 vgs/cells of either pscAAV-CMV-CD or pscAAV-CMV-CD-379 
miR199a*3 as previously described.  380 
3D culture of Hepa1-6 381 
3D tumorspheres of Hepa1-6 were maintained in stem cell conditioned, serum free NSA 382 
media containing DMEM/F12 (Thermo Fisher Scientific), 10ng/ml recombinant human basic 383 
fibroblast growth factor (rhFGF) (Lonza), 20ng/ml recombinant human epidermal growth 384 
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factor (rhEGF) (Lonza), bovine serum albumin (BSA) (Sigma Aldrich), 4µg/ml heparin 385 
sulfate (Sigma Aldrich), and 1% P/S (Thermo Fisher Scientific) as previously described 42. 386 
Briefly, 30,000 cells were collected, washed thrice with PBS and seeded in ultra-low 387 
attachment plates (Corning, NY, USA). Images of tumorspheres were taken with a digital 388 
camera (Olympus DP21, Japan) connected to an inverted microscope (Olympus CKX41) 389 
with imaging software (CellSens, Olympus, Japan). Cells were either collected for RNA 390 
extraction (day 5), transfected at day 3 (with CMV-GLuc or CMV-GLuc-miR199a*3), or 391 
transduced at day 3 (with pscAAV8-GLuc) or pscAAV8-GLuc-miR199a*3). 392 
Statistical analysis 393 
All experiments were repeated at least thrice, and data represented as mean ± SD. To test 394 
whether there were significant differences in experimental results between groups, two tailed 395 
t-test was performed with Graph Pad Prism 7.0 (GraphPad Software, Inc.) (* <0.05, ** <0.01, 396 
***<0.001).  397 
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Figure Legends 555 
Figure 1: Expression pattern of miRNA199a: The expression levels of miRNA199a was 556 
measured by quantitative real time PCR and was performed in primary hepatocytes, HepaRG 557 
and a panel of HCC (a) and non-HCC cell lines (b). The copies of miRNA199a was 558 
normalized against that of the RNU6 control and represented as the number of copies per 559 
1000 control. (n>3 for all cell lines except HUM4150) 560 
Figure 2: Reporter gene expression under the control of miRNA199a binding sites: (a) 561 
Principle of miRNA mediated detargeting: Inclusion of binding sites of miRNA expressed at 562 
high levels in a cell can limit the expression of transgene in that particular cell while minimal 563 
effects is expected in cells that don’t express the miRNA. (b) To study the effect of the 564 
presence of miRNA199a binding sites at the 3’-UTR of a transgene, miRNA199a positive 565 
cells HepaRG, and Hepa1-6 were transfected with CMV-GLuc and CMV-GLuc-miR199a*3; 566 
GLuc expression with CMV-GLuc-miR199a*3 was reported as a percentage of CMV-GLuc. 567 
Similarly, miRNA199a negative HCC cell lines (c) and non-HCC cell lines (d) were 568 
transfected with CMV-GLuc and CMV-GLuc-miR199a*3 and the amount of secreted GLuc 569 
was quantified. (e) Further confirmation of miRNA199a mediated gene regulation was 570 
performed by transfection of Hepa1-6 cells with CMV-eGFP and CMV-eGFP-miR199a*3; 571 
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72 hours post transfection, the percentage of GFP positive cells was quantified with flow 572 
cytometry and the percentage of GFP positive cells after transfection with CMV-eGFP-573 
miR199a*3 was normalized with CMV-eGFP. Two tailed t-test was used for statistical 574 
analysis to compare percentage expression of CMV-GLuc-miR199a*3 or CMV-eGFP-575 
miR199a*3 with CMV-GLuc or CMV-eGFP respectively for both HepaRG and Hepa1-6 576 
using Graph Pad Prism 7.0. (n>3, ** p<0.005, *** p<0.001)  577 
Figure 3: Overexpression and inhibition of miRNA199a and its effect on the expression 578 
of reporters containing miRNA199a binding sites at the 3’-UTR: To investigate the 579 
effects of inhibiting miRNA199a on the expression of reporter genes with binding site at the 580 
3’-UTR, Hepa1-6 cells were co-transfected with either CMV-eGFP or CMV-eGFP-581 
miR199a*3 and miRNA199a inhibitor (a), and either CMV-GLuc or CMV-GLuc-582 
miR199a*3 and miRNA199a inhibitor (c). The percentage of GFP positive cells for each 583 
group was quantified with flow cytometry and expressed as percentage of GFP positive cells 584 
after transfection with CMV-eGFP. Similarly, the amount secreted luciferase was quantified 585 
and expressed as a percentage of quantity of secreted luciferase after transfection with CMV-586 
GLuc for each treatment group. (b) Representative fluorescent microscope and flow 587 
cytometry images for each treatment groups. (d) The effects of overexpressing miRNA199a 588 
on reporter expression in HCC cell lines by co-transfecting either CMV-GLuc or CMV-589 
GLuc-miR199a*3 and miRNA199a mimic was studied. The secreted luciferase was 590 
quantified and represented as percentage of secreted luciferase after transfection with CMV-591 
GLuc for each treatment group. Two tailed t-test was performed to compare the difference 592 
between indicated groups using Graph Pad 7.0 (n>3, * p<0.05)  593 
Figure 4: Targeted gene directed enzyme prodrug therapy (GDEPT) utilizing 594 
miRNA199a binding site: (a) Cells were seeded in a 96-well plate and transfected with 595 
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CMV-CD and CMV-CD-miR199a*3; after incubation with 5-FC, MTS assay was performed 596 
to quantify cell proliferation. Percentage proliferation with CMV-CD-199a*3 was normalized 597 
with CMV-CD for each cell line. (b) In order to quantify total cell death after GDEPT, cells 598 
were transfected in 24 well plates with CMV-CD and CMV-CD-miR199a*3 and incubated 599 
with media containing 5-FC. Percentage of apoptotic cells were then calculated by 600 
annexin/propidium iodide (PI) staining. Percentage death after GDEPT with CMV-CD-601 
199a*3 was normalized against that with CMV-CD. (c) Representative flow cytometric 602 
analysis of Hepa1-6 showing the difference of apoptotic cells after GDEPT with CMV-CD, 603 
and CMV-CD-miR199a*3. (d) Representative flow cytometric images of miRNA199a 604 
positive Hepa1-6 and miRNA199a negative Hep3B, PLC/PRF/5, and SKHep1 showing 605 
percentage of annexin and PI positive cells after GDEPT with CMV-CD and CMV-CD-606 
miR199a*3. Experiments were repeated thrice in triplicates and the difference between 607 
CMV-CD and CMV-CD-miR199a groups was checked for statistical significance using the 608 
two tailed t-test in Graph Pad Prism 7.0 (*p< 0.05 ***p<0.005) 609 
Figure 5: Adeno associated virus (AAV) vector system mediated targeted gene therapy 610 
based on post-transcriptional action of miRNA199a: To investigate the possibility of 611 
vector mediated delivery of transgene harboring miR199a binding site, AAV8 harboring 612 
GLuc as reporter and cytosine deaminase (CD) as therapeutic gene was constructed with or 613 
without miR199a binding sites at the 3’-UTR of the transgenes and cells were transduced at 614 
an MOI of 100,000 vgs/cell. (a) Construction of plasmid harboring GLuc, and CD flanked by 615 
self-complementary inverted terminal repeats of the Adeno associated virus. (b) Reporter 616 
expression after delivery with AAV: Both miRNA199a positive and negative cells were 617 
transduced with scAAV8-GLuc and scAAV8-GLuc-miR199a*3 and the amount of secreted 618 
GLuc was quantified. Relative expression of GLuc after transduction with scAAV8-GLuc-619 
miR199a*3 was reported as a percentage of that after transduction with scAAV8-GLuc.   (b) 620 
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Targeted GDEPT after AAV mediated suicide gene therapy: Cells were transduced with 621 
scAAV8-CD, and scAAV8-CD-miR199a*3 and incubated with the prodrug 5-FC. The 622 
percentage proliferation was then calculated for scAAV8-CD-miR199a*3 and represented as 623 
a percentage of that for scAAV8-CD for each cell type. The significant difference between 624 
groups was tested by two-tailed t-test using Graph Pad prism 7.0. (n>3, *<0.05). 625 
Figure 6: Expression of miRNA199a in stem cell enriched tumorspheres of Hepa1-6 and 626 
its implication for targeted gene delivery: (a) Photomicrographs of tumorspheres of 627 
Hepa1-6 after 5 days in culture in serum free, stem cell enriching media (scale bar = 50µM). 628 
Quantitative real time PCR was performed on cDNA of the Hepa1-6 and Hepa1-6 629 
tumorspheres to compare the markers of stemness, CD44 (b), CD133 (c), and Oct4 (d) as 630 
well as miRNA199a (e) Comparison of miRNA199a levels in Hepa1-6 and Hepa1-6 631 
tumorspheres. (f) Hepa1-6 and Hepa1-6 tumorspheres were transfected with CMV-GLuc-632 
miR199a*3 and secreted GLuc was reported as percentage of CMV-GLuc (g) Hepa1-6 and 633 
Hepa1-6 tumorspheres were transduced with pscAAV8-GLuc and pscAAV8-GLuc-634 
miR199a*3 and relative GLuc expression was reported. (h) Similarly, Hepa1-6 and Hepa1-6 635 
tumorspheres were transfected with CMV-CD and CMV-CD-miR199a*3 and percentage 636 
proliferation was calculated following incubation with 5-FC. Percentage proliferation for 637 
CMV-CDmiR199a*3 was normalized with CMV-CD. Two tailed t-test was performed to 638 
analyze the difference between groups. (n>3, *<0.05, **<0.01). 639 
 640 
 641 
 642 
 643 
 644 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
(a)
(b)
A
5
4
9
H
4
6
0
9
2
.1
M
e
l2
0
2
M
e
l2
7
0
M
C
F
7
T
4
7
D
L
n
C
a
p
D
U
1
4
5
S
W
6
2
6
C
a
o
V
3
T
O
V
2
1
G
H
E
K
2
9
3
C
O
S
-7
J
u
r
k
a
t
A
R
P
E
-1
9
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
C
o
p
ie
s
 p
e
r
 1
0
0
0
 c
o
n
tr
o
l
O va ria n
c a n c e r
M e la n om a
L u n g
c a n c e r
B re a s t
c a n c e r
P ro s ta te
c a n c e r
K id n e y T -c e ll
R e tin a l p ig m e n ta l e p ith e liu m
m iR N A  1 9 9 a
H
U
M
4
1
5
0
H
e
p
a
R
G
H
e
p
a
1
-6
 
H
e
p
3
B
S
K
H
e
p
1
P
L
C
/P
R
F
/5
  
S
N
U
4
2
3
 
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
C
o
p
ie
s
 p
e
r
 1
0
0
0
c
o
n
tr
o
l
m iR N A 1 9 9 a
H u m a n  H e p a to c y te s
H u m a n  H C C
M o u s e  H C C
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
(d)
(a) (b)
H
4
6
0
A
5
4
9
9
2
.1
M
e
l2
7
0
M
C
F
7
T
4
7
D
L
n
C
a
p
D
U
1
4
5
S
W
6
2
6
C
a
o
V
3
T
O
V
2
1
G
H
E
K
2
9
3
C
O
S
-7
A
R
P
E
-1
9
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
E
x
p
re
s
s
io
n
(c)
CMV-eGFP
GFP positive cells = 74.9%
CMV-eGFP-miR199a*3
GFP positive cells = 14.3%
1.2 76.1 15.1
Hepa1-6
H
e
p
a
R
G
H
e
p
a
1
-6
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
E
x
p
r
e
s
s
io
n
CM V -G L u c
C M V -G L u c -m iR 1 9 9 a *3
* *
* * *
(e)
H
e
p
a
1
-6
  
0
5 0
1 0 0
1 5 0
P
e
r
c
e
n
ta
g
e
 o
f 
G
F
P
 p
o
s
it
iv
e
 c
e
ll
s
(C
M
V
-e
G
F
P
=
1
0
0
)
CM V -eG FP
CM V -eG FP -m iR 1 99 a *3
* * *
H
e
p
3
B
 
S
K
H
e
p
1
 
P
L
C
/P
R
F
/5
  
  
 
S
N
U
4
2
3
 
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
E
x
p
r
e
s
s
io
n
CM V -G L u c
C M V -G L u c -m iR 1 9 9 a *3
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
E
x
p
r
e
s
s
io
n
H e p 3B
C M V -G L u c -m iR 1 9 9 a *3
C M V -G L u c
C M V -G L u c  +  m im ic
C M V -G L u c -m iR 1 9 9 a *3  +  m im ic
(a)
*
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
E
x
p
r
e
s
s
io
n
S K H e p 1
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
E
x
p
re
s
s
io
n
S N U 4 23
*
**
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
E
x
p
r
e
s
s
io
n
H e p a 1 -6
C M V -G L u c
C M V -G L u c  +  in h ib ito r
C M V -G L u c -m iR 1 9 9 a *3
C M V -G L u c -m iR 1 9 9 a *3  +  in h ib ito r
0
5 0
1 0 0
1 5 0
P
e
r
c
e
n
ta
g
e
 o
f 
G
F
P
p
o
s
it
iv
e
 c
e
ll
s
(C
M
V
-e
G
F
P
=
1
0
0
)
H e p a 1 -6
C M V -e G F P
C M V -e G F P  + m iR N A 1 9 9 a   in h ib ito r
C M V -e G F P -m iR 1 9 9 a *3
C M V -e G F P -m iR 1 9 9 a *3  +  m iR N A 1 9 9 a  in h ib ito r
*
CMV-eGFP-
miR199a*3
26.2%
CMV-eGFP
60.78%
CMV-eGFP + 
miRNA199a inhibitor
52.5%
CMV-eGFP-miR199a*3 + 
miRNA199a inhibitor
43.98%
Control
(b)
(c)
(d)
*
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
E
x
p
r
e
s
s
io
n
P L C /P R F /5
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
(a) (c)
(b)
A
n
n
exin
PI
Hepa1-6
(d)
H
e
p
a
1
-6
 
H
e
p
3
B
 
P
L
C
/P
R
F
/5
S
K
H
e
p
1
S
N
U
4
2
3
 
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
P
e
r
c
e
n
ta
g
e
 P
r
o
li
fe
r
a
ti
o
n
(C
M
V
-C
D
=
1
0
0
)
C M V -C D
CM V -C D -m iR 1 9 9a
*
H
e
p
a
1
-6
 
H
e
p
3
B
 
P
L
C
/P
R
F
/5
S
K
H
e
p
1
 
0
5 0
1 0 0
1 5 0
P
e
r
c
e
n
ta
g
e
 D
e
a
th
(C
M
V
-C
D
=
1
0
0
)
CM V -C D -m iR 1 9 9a
C M V -C D
* * *
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT(a)
(b) (c)
H
e
p
a
1
-6
 
H
e
p
3
B
 
P
L
C
/P
R
F
/5
S
K
H
e
p
1
 
S
N
U
4
2
3
 
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 l
u
c
if
e
r
a
s
e
 e
x
p
r
e
s
s
io
n
(s
c
A
A
V
8
-G
L
u
c
=
1
0
0
)
s cA A V 8 -G L u c
s cA A V 8 -G L u c -m iR 1 9 9 a *3
*
H
e
p
a
1
-6
 
H
e
p
3
B
 
P
L
C
/P
R
F
/5
S
K
H
e
p
1
 
S
N
U
4
2
3
 
0
2 0 0
4 0 0
6 0 0
P
e
r
c
e
n
ta
g
e
 p
r
o
li
fe
r
a
ti
o
n
(s
c
A
A
V
8
-C
D
=
 1
0
0
)
s cA A V 8 -C D
s cA A V 8 -C D -m iR 1 9 9 a *3
*
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
(a)
(b)
(e)(d)
50μM
(c)
(f)
(g)
H
e
p
a
1
-6
  
 
H
e
p
a
1
-6
 t
u
m
o
u
r
s
p
h
e
r
e
s
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
E
x
p
re
s
s
io
n
(C
M
V
-G
L
u
c
=
1
0
0
 p
e
rc
e
n
t)
*
H
e
p
a
1
-6
  
 
H
e
p
a
1
-6
 t
u
m
o
u
r
s
p
h
e
r
e
s
0
5 0
1 0 0
1 5 0
R
e
la
ti
v
e
 L
u
c
if
e
r
a
s
e
 e
x
p
r
e
s
s
io
n
(p
s
c
A
A
V
8
-G
L
u
c
=
1
0
0
 p
e
r
c
e
n
t)
* *
(h)
H
e
p
a
1
-6
  
 
H
e
p
a
1
-6
 t
u
m
o
u
r
s
p
h
e
r
e
s
0
5 0
1 0 0
1 5 0
P
e
rc
e
n
ta
g
e
 c
e
ll
 d
e
a
th
(C
M
V
-C
D
=
1
0
0
 p
e
r
c
e
n
t)
* * *
H
e
p
a
1
-6
 
H
e
p
a
1
-6
 t
u
m
o
r
s
p
h
e
r
e
s
0
5 0
1 0 0
1 5 0
2 0 0
C
o
p
ie
s
 p
e
r
 1
0
0
0
c
o
n
tr
o
l
*
C D 44
H
e
p
a
1
-6
 
H
e
p
a
1
-6
 t
u
m
o
r
s
p
h
e
r
e
s
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
C
o
p
ie
s
 p
e
r
 1
0
0
0
c
o
n
tr
o
l
*
C D 1 33
H
e
p
a
1
-6
 
H
e
p
a
1
-6
 t
u
m
o
r
s
p
h
e
r
e
s
0
2 0 0
4 0 0
6 0 0
C
o
p
ie
s
 p
e
r
 1
0
0
0
c
o
n
tr
o
l
*
OCT4
H
e
p
a
1
-6
 
H
e
p
a
1
-6
 t
u
m
o
r
s
p
h
e
r
e
s
0
5 0 0
1 0 0 0
1 5 0 0
C
o
p
ie
s
 p
e
r 
1
0
0
0
c
o
n
tr
o
l
*
m iR NA 199a
200μM
